Guideline: Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand [2008]

Developers: Cancer Council Australia, Australian Cancer Network, Ministry of Health, New Zealand

Summary: This is a high-quality guideline that can be used to guide preventive care in Canada. Although the incidence of melanoma is lower in Canada than in Australia and New Zealand, the recommendations seem sensible and applicable for use in Canadian practice.

OVERVIEW These guidelines were developed for use in 2 countries with a very high incidence of melanoma. From 1998 to 2002, the age-standardized incidence rate of melanoma in Australia and New Zealand ranged from 21.7 to 55.8 per 100,000 population, depending on sex and region. Comparatively, the age-standardized incidence of skin melanoma in Canada was 15.7 per 100,000 in 2007.

Most melanomas are the result of exposure to ultraviolet radiation from the sun, and survival has been associated with depth of invasion, which suggests a role for early detection. Therefore, this guideline focuses on prevention, screening, and identification and management of individuals at high risk of melanoma.

RELEVANCE TO CTFPHC MANDATE The following sections of this guideline are applicable to the CTFPHC mandate of prevention in primary care:

- Section 1: Prevention
- Section 2: Population-based whole-body skin screening for melanoma
- Section 3: Identification of high-risk individuals

POPULATION The target population for this guideline is not clearly stated; however, on the basis of the recommendations, it can be inferred that it applies to people of all ages and all ethnic backgrounds.

EVIDENCE REVIEW METHODS The following databases were searched from mid-2006 to early 2007: MEDLINE, Embase, PubMed, CINAHL, Cochrane Library, AUSThealth, Clinical Evidence, and PsycINFO. Reference lists of relevant articles were hand searched. The specific research questions are unknown.

GRADING SYSTEM Each recommendation was assigned a grade of A to D, based on features of the body of evidence, including volume, consistency, generalizability, applicability and clinical impact. “Good practice points” refer to statements made by the developer that could not be graded (Table 1).

COMMENTARY The scope and purpose of this guideline are clearly described, with good separation of screening from diagnosis and case-finding. The recommendations are presented clearly, with links to the supporting evidence. Further, the guideline development group included individuals from all relevant disciplines, as well as a consumer representative, and the views and preferences of patients were sought through public review.

However, the rigour of development scored relatively low, primarily because methodological details (research questions, inclusion and exclusion criteria) were only available upon request (information not received), making it difficult to determine whether the included evidence is appropriate. There is also a lack of discussion about facilitators and barriers to the application of these recommendations, which would have been helpful for family physicians. Although these recommendations are based on evidence obtained in early 2007, the guideline states that updates will be posted online if needed. Methods are provided for addressing conflicts of interest, but the CTFPHC did not identify any evidence of such conflicts.

Overall, this guideline provides clear and concise recommendations for prevention, screening and identification of individuals at high risk of melanoma. Although the incidence of melanoma is lower in Canada than in Australia and New Zealand, the recommendations seem sensible and applicable for use in Canadian practice.

CTFPHC APPRAISAL COLOUR LEGEND

This is a high-quality guideline that can be used to guide preventive care in Canada.

This is a high-quality guideline, but the CTFPHC has identified some concerns that may limit its applicability.

This is a high-quality guideline, but the CTFPHC does not recommend its use in Canada.

PLEASE VISIT WWW.CANADIANTASKFORCE.CA FOR ADDITIONAL INFORMATION
Recommendations (excerpt): Cancer Council Australia, Australian Cancer Network, Ministry of Health, New Zealand

The full guideline can be found at: http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines-ManagementofMelanoma.pdf

PREVENTION OF MELANOMA

1. Sunburn be avoided and UV protection (physical methods complemented by sunscreens) adopted [Grade B].
2. Sunscreens be used to complement but not to replace physical methods of UV protection [Grade C].
3. Risks associated with exposure to tanning booths and sunbeds be explained [Grade C].
4. As brief sun exposures are needed to maintain vitamin D levels, total lack of sun exposure is not advised without vitamin D supplementation [Grade C].

POPULATION SCREENING FOR MELANOMA

1. In the absence of substantive evidence as to its effectiveness in reducing mortality from melanoma, population-based skin screening cannot be recommended [Grade C].

IDENTIFICATION AND MANAGEMENT OF HIGH-RISK INDIVIDUALS

1. Clinical assessment of future risk of melanoma take into account:
   - person’s age and sex
   - history of previous melanoma or non-melanoma skin cancer
   - family history of melanoma
   - number of naevi (common and atypical)
   - skin and hair pigmentation
   - response to sun exposure
   - evidence of actinic skin damage [Grade B]

2. Individuals at high risk of melanoma and their partner or carer be educated to recognise and document lesions suspicious of melanoma, and to be regularly checked by a clinician with six-monthly full body examination supported by total body photography and dermoscopy as required [Grade C].

Good practice point: Prophylactic removal of non-suspicious lesions is not recommended since it is unlikely to increase survival and therefore may incur unnecessary procedures and give false reassurance as many new melanomas in high-risk individuals will occur outside pre-existing naevi.

3. Screening for a genetic mutation such as the CDKN2A gene be contemplated only after a thorough clinical risk assessment (the patient is at personal high risk of melanoma), confirmation of a strong family history of melanoma (there is a significant probability of a family mutation), and appropriate genetic counselling [Grade C].

TABLE 1 (BELOW): Description of recommendation grading scheme1:

<table>
<thead>
<tr>
<th>GRADE A</th>
<th>Body of evidence can be trusted to guide practice.</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRADE B</td>
<td>Body of evidence can be trusted to guide practice in most situations.</td>
</tr>
<tr>
<td>GRADE C</td>
<td>Body of evidence provides some support for recommendation(s) but care should be taken in its application.</td>
</tr>
<tr>
<td>GRADE D</td>
<td>Body of evidence is weak and recommendation must be applied with caution.</td>
</tr>
<tr>
<td>GOOD PRACTICE POINT</td>
<td>Expert opinion.</td>
</tr>
</tbody>
</table>

REFERENCES